Free to browse, no account needed
Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Drugs A–Z › Prasugrel
Approved
FDA, Jul 2009
1
Registered trials
What is Prasugrel?
Prasugrel is a P2Y12 receptor antagonist that irreversibly binds to ADP receptors on platelets to inhibit platelet activation and aggregation.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as Effient Drug type Small molecule
Targets
P2Y12 receptor (P2RY12)
Mechanism Antagonist of P2Y12 receptor (P2RY12) Pathways platelet activation and aggregation Therapy area Cardiovascular Developer
Cosette
In trials of COLL FDA status
Approved as Effient (July 10, 2009), NDA022307 · FDA label
✅ FDA-approved uses
Acute coronary syndrome (unstable angina or NSTEMI)
ST-elevation myocardial infarction (STEMI) managed with PCI
From the indications section of the FDA label (version of Sep 7, 2022). Read the full label for the exact wording, limitations and safety information.
🧪 Clinical trials
Trial Phase Condition Status Sponsor
NCT05779059 Phase 3
Non ST Segment Elevation Acute Coronary Syndrome
Unknown
COLL
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Conditions studied
Non ST Segment Elevation Acute Coronary Syndrome Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) Unstable Angina
Other drugs acting on P2RY12
Sources
Updated Oct 3, 2026.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z